Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 3;55(4):779–793. doi: 10.1038/s12276-023-00961-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Comparing the gene expression of SAMHD1 in various cancer types using the TCGA database. KIPAN, pankidney cancer; GBMLGG, glioma; UCEC, uterine corpus endometrial carcinoma; LIHC, liver hepatocellular carcinoma; THCA, thyroid carcinoma; COADREAD, colorectal adenocarcinoma; BLCA, bladder urothelial carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. b Comparison of SAMHD1 mRNA expression between tumor and normal tissues according to histological RCC subtypes. ***p < 0.001. c Comparative mRNA expression of SAMHD1 between paired tumor and nontumor tissues according to histological RCC subtypes. ***p < 0.001. d Kaplan–Meier analysis of 5-year overall survival (OS) between SAMHD1 high expression (n = 77) and SAMHD1 low expression groups (n = 303). Log-rank p = 0.004. e Kaplan–Meier analysis of progression-free survival (PFS) between SAMHD1 high expression (n = 78) and SAMHD1 low expression groups (n = 300). Log-rank p = 0.002. f Immunohistochemistry (IHC) of SAMHD1 in ccRCC tissues. Scale bar, 50 μm. g Immunoblotting was used to analyze the protein level of SAMHD1 in 20 paired cancer and normal tissues. SAMHD1 protein levels were normalized to corresponding β-actin levels. **p < 0.01. h SAMHD1 protein levels normalized to β-actin levels in ccRCC tissues according to patient prognosis were analyzed by western blotting. *p < 0.05. Data are presented as the mean ± SD. i Representative western blot bands are presented with the corresponding prognosis.